Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | RB1 del SMARCB1 loss |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| RB1 del SMARCB1 loss | rhabdoid cancer | sensitive | Seliciclib | Preclinical - Cell culture | Actionable | In a preclinical study, Roscovotine (seliciclib) inhibited viability of a SMARCB1-deficient rhabdoid cancer cell line with a deletion of RB1 in culture (PMID: 38315003). | 38315003 | |
| RB1 del SMARCB1 loss | rhabdoid cancer | sensitive | Alisertib | Preclinical - Cell culture | Actionable | In a preclinical study, Alisertib (MLN8237) inhibited viability of a SMARCB1-deficient rhabdoid cancer cell line with a deletion of RB1 in culture (PMID: 38315003). | 38315003 | |
| RB1 del SMARCB1 loss | rhabdoid cancer | sensitive | Barasertib | Preclinical - Cell culture | Actionable | In a preclinical study, Barasertib (AZD1152) inhibited viability of a SMARCB1-deficient rhabdoid cancer cell line with a deletion of RB1 in culture (PMID: 38315003). | 38315003 | |
| RB1 del SMARCB1 loss | rhabdoid cancer | resistant | Tazemetostat | Preclinical - Cell culture | Actionable | In a preclinical study, a SMARCB1-deficient rhabdoid cancer cell line with a deletion of RB1 was resistant to Tazverik (tazemetostat) in culture (PMID: 38315003). | 38315003 |